ESSA Pharma logo

ESSA PharmaNASDAQ: EPIX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

13 March 2015

Next earnings report:

12 December 2024

Last dividends:

N/A

Next dividends:

N/A
$76.76 M
-87%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:54:21 GMT
$1.73+$0.01(+0.58%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

EPIX Latest News

EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc.
accesswire.com14 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.

EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc.
accesswire.com11 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.

EPIX STOCK ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of an Ongoing Investigation
accesswire.com06 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.

ESSA Pharma Inc. (EPIX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
accesswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.

Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect
accesswire.com03 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX). Investors who purchased ESSA securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EPIX.

ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
accesswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX). Investors who purchased ESSA securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EPIX.

What type of business is ESSA Pharma?

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

What sector is ESSA Pharma in?

ESSA Pharma is in the Healthcare sector

What industry is ESSA Pharma in?

ESSA Pharma is in the Biotechnology industry

What country is ESSA Pharma from?

ESSA Pharma is headquartered in Canada

When did ESSA Pharma go public?

ESSA Pharma initial public offering (IPO) was on 13 March 2015

What is ESSA Pharma website?

https://www.essapharma.com

Is ESSA Pharma in the S&P 500?

No, ESSA Pharma is not included in the S&P 500 index

Is ESSA Pharma in the NASDAQ 100?

No, ESSA Pharma is not included in the NASDAQ 100 index

Is ESSA Pharma in the Dow Jones?

No, ESSA Pharma is not included in the Dow Jones index

When was ESSA Pharma the previous earnings report?

No data

When does ESSA Pharma earnings report?

The next expected earnings date for ESSA Pharma is 12 December 2024